Some of the medications most significantly associated with the clinical outcomes were calcium supplements for osteoporosis (p-value = 2.77 × 10−18); metformin for type 2 diabetes (p-value < 1.00 × 10−20); antihypertensive medications for hypertension (p-value < 9.58 × 10−5); statins for hypercholesterolemia (HMG CoA reductase inhibitors: p-value < 1.00 × 10−20); and benzodiazepine derivatives and antidepressants for major depressive disorder (Table 1 and Supplementary Table S3). This evidence concerns the gene HMGCR and familial hypercholesterolemia.